List view / Grid view
15 July 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer...
14 July 2014 | By Teva
First breath-actuated dry-powder SABA inhaler to be accepted by FDA for review...
14 July 2014 | By Abbott
Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company...
14 July 2014 | By Roche
Roche announced that the Phase III coBRIM study met its primary endpoint...
11 July 2014 | By Innopharma Labs
Glatt and Innopharma Labs enter into a partnership to enable customers to profit from EyeconTM in-line particle characterisation...
11 July 2014 | By Abbott
A proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott has made in China...
11 July 2014 | By Sanofi
Sanofi Pasteur, the vaccines division of Sanofi announced the publication in The Lancet of the detailed results of its first landmark phase III dengue vaccine efficacy study conducted in five countries in Asia...
11 July 2014 | By Bristol-Myers Squibb
...an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma...
10 July 2014 | By kdm communications
Cresset announces the appointment of CloudScientific as distributor of their computational chemistry software in China...
10 July 2014 | By Pfizer
CliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. and Pfizer Inc. to jointly advance the parties’ respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health...
10 July 2014 | By Sanofi
Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
9 July 2014 | By Fraunhofer
The operative business of European ScreeningPort GmbH has been integrated into the Fraunhofer Institute for Molecular Biology and Applied Ecology IME located in Aachen...
9 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Dalfampridine Extended-release Tablets, 10 mg...
9 July 2014 | By Novartis
Novartis has published a Corporate Responsibility (CR) Performance Report for 2013...
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
